Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

liposome-incorporated Grb2 antisense oligodeoxynucleotide

A liposomal formulation containing the antisense oligodeoxynucleotide (ODN) growth factor receptor-bound protein 2 (Grb2), with potential antineoplastic activity. Upon administration, liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of cancer cells overexpressing Grb2. Grb2, an adaptor protein involved in growth signaling pathways, is upregulated in certain tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	grb2 mRNA liposomal Grb-2 liposomal Grb2 AS ODN
Abbreviation:	L-Grb-2 L-Grb2
Code name:	BP-100-1.01 BP1001

liposome-incorporated Grb2 antisense oligodeoxynucleotide

Search NCI's Drug Dictionary